Michael Thomas Heneka, Prof. Dr. med.
German, male

Academic Qualifications

2016-present	Full Professor (W3), Director of the Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn
2013-present	Adjunct Professor, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
2010-present	Cooperation Unit Leader Neuroinflammation, German Center for Neurodegenerative Diseases (DZNE), Bonn

Postgraduate Professional Career

2010-2016	Head of the Neurodegeneration Outpatient Unit, University Hospital Bonn
2004-2008	C3 Professor of Molecular Neurology and Senior Clinical Fellow, Department of Neurology, University of Münster
2003-2004	Senior Clinical Fellow, Department of Neurology, University Hospital Bonn
2002	Board certification Clinical Neurology, University Hospital Bonn

Research Expertise

Prof. Heneka and his group are involved in basic science and translational research with a focus on neurodegeneration and neuroinflammation. Major diseases of interest and research topics include Alzheimer's disease, amyotrophic lateral sclerosis, septic encephalopathy and multiple sclerosis. In clinical neurology, Prof. Heneka holds special expertise in neurodegenerative and autoimmune CNS disorders.

Honors and Awards

2018-present	Editorial Board, *ASN Neuro*
2019	Highly cited researcher "interdisciplinary"
2019-present	Associate Editor, *Alzheimer Research & Therapy*
2016-2019	Editorial Board, *Alzheimer Research & Therapy*
2014-present	Associate Editor, *Neurology 'Neuroimmunology and Neuroinflammation'*
2013-present	Program Committee Member, Society for Neuroscience, U.S.A.
2012-present	Steering Committee Member, Cluster of Excellence "ImmunoSensation/ ImmunoSensation^2", University of Bonn
2012-present	Executive Board Member, Else-Kröner-Research College, Bonn
2012-present	Executive Board Member, Task Force "Dementia" of the European Federation of Neurological Societies (EFNS)
2012-present	Editorial Board, *Molecular Neurobiology*
2008-present	Editorial Board, *Journal of Neurochemistry*
2007-present	Expert Panel Member „S3 guideline for dementia"
2013	Hans und Ilse Breuer Alzheimer Research Award
2011	Christa Lorenz ALS Research Prize
2007-2013	Speaker, DFG Clinical Research Unit 177 "Innate Immunity in Chronic Neurodegeneration", University of Bonn
2007-2010	Executive Board Member, Network of Competence "Degenerative Dementia" (KNDD) of the Federal Ministry for Education and Science (BMBF)
1999	Attempto Award, University of Tübingen
1990-1996	Fellow of the 'Studienstiftung des deutschen Volkes' (German National Academic Foundation)

Selected Publications

1. Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S.V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R., Tejera, D., Griep, A., Santarelli, F., Brosseron, F., Opitz, S., Stunden, J., Merten, M., Kayed, R., Golenbock, D.T., Blum, D., Latz, E., Buée, L., Heneka, M.T. (2019). NLRP3 inflammasome activation drives tau pathology. ***Nature***, *575*, 669-673.

2. Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, Vieira-Saecker A, Schwartz S, Santarelli F, Kummer MP, Griep A, Gelpi E, Beilharz M, Riedel D, Golenbock DT, Geyer M, Walter J, Latz E, **Heneka MT**. (2017) Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease. ***Nature*** 552(7685):355-361

3. Willem, M., Tahirovic, S., Busche, M.A., Ovsepian, S.V., Chafai, M., Kootar, S., Hornburg, D., Evans, L.D., Moore, S., Daria, A., Hampel, H., Muller, V., Giudici, C., Nuscher, B., Wenninger-Weinzierl, A., Kremmer, E., **Heneka, M.T.**, Thal, D.R., Giedraitis, V., Lannfelt, L., Muller, U., Livesey, F.J., Meissner, F., Herms, J., Konnerth, A., Marie, H., and Haass, C. (2015). eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. ***Nature*** 526, 443-447.

4. **Heneka, M.T**., Kummer, M.P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.C., Gelpi, E., Halle, A., Korte, M., Latz, E., and Golenbock, D.T. (2013). NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. ***Nature*** 493, 674-678.

5. Kummer, M.P., Hermes, M., Delekarte, A., Hammerschmidt, T., Kumar, S., Terwel, D., Walter, J., Pape, H.C., Konig, S., Roeber, S., Jessen, F., Klockgether, T., Korte, M., and **Heneka, M.T.** (2011). Nitration of tyrosine 10 critically enhances amyloid beta aggregation and plaque formation. ***Neuron*** 71, 833-844.